Key result
Pulsed field ablation eliminates atrio-oesophageal fistula and minimizes permanent phrenic nerve injury, while introducing rare risks of coronary spasm (0.10-0.14%) and haemolysis-related AKI (0.03%).
Why the study?
Although pulsed field ablation reduces traditional thermal ablation complications, it introduces a distinct spectrum of physiologic effects—including coronary vasospasm, haemolysis, silent cerebral lesions, and cardiac implantable electronic device interactions—that require safety consideration and clinical monitoring.
What are the technology-specific safety considerations, physiological mechanisms of adverse events, and mitigation strategies during pulsed field ablation compared with thermal ablation in patients undergoing cardiac arrhythmia ablation?
What are the technology-specific safety considerations, physiological mechanisms of adverse events, and mitigation strategies during pulsed field ablation compared with thermal ablation in patients undergoing cardiac arrhythmia ablation?
While pulsed field ablation substantially reduces traditional thermal complications like atrio-oesophageal fistula and pulmonary vein stenosis, clinicians must actively monitor and mitigate PFA-specific risks including coronary vasospasm, dose-dependent haemolysis, silent cerebral emboli, and CIED interactions.
Mandates monitoring for coronary spasm and haemolysis-related AKI during PFA; leaves open need for randomized outcome trials versus thermal ablation.
Pulsed field ablation (PFA) has emerged as a transformative technology in cardiac electrophysiology, offering a potentially superior safety profile compared with thermal ablation due to its non-thermal mechanism of irreversible electroporation. Clinical experience confirms a substantial reduction in traditional complications such as pulmonary vein stenosis, atrio-oesophageal fistula, and permanent phrenic nerve injury, though PFA introduces a distinct spectrum of physiologic effects requiring consideration. Coronary vasospasm is the most characteristic phenomenon, ranging from transient, subclinical constriction to rare ischaemic or arrhythmic events; mitigation relies on coronary anatomical awareness, optimized lesion placement, and prophylactic vasodilators. Haemolysis, caused by red blood cell electroporation, varies with catheter design and pulse burden and is typically mild, though high exposure and inadequate hydration may rarely lead to acute kidney injury. Silent cerebral lesions could result from procedural and/or energy-related factors, including gas formation, air ingress, catheter manipulation, and anticoagulation management, with uncertain long-term clinical impact but opportunities for technique-driven reduction. Interactions between PFA and cardiac implantable electronic devices are system- and context-dependent, with monopolar configurations and catheter-lead proximity influencing the risk of transient interference and rare permanent damage.
No takes yet. Share an insight, caveat, or question.
Defaye et al. (2026) conducted a review in Cardiac arrhythmias (primarily atrial fibrillation) treated with pulsed field ablation. Pulsed field ablation (PFA) vs. Thermal ablation (radiofrequency and cryoballoon ablation) was evaluated on Technology-specific safety profile and adverse events (coronary vasospasm, haemolysis, silent cerebral lesions, CIED interactions). Pulsed field ablation eliminates atrio-oesophageal fistula and minimizes permanent phrenic nerve injury, while introducing rare risks of coronary spasm (0.10-0.14%) and haemolysis-related AKI (0.03%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: